Every clinician who treats addiction has heard the same objection, sometimes from a family member and sometimes from the patient. Everyone likes things that feel good, so why can one person enjoy a good meal and walk away, while another cannot walk away from heroin? For a long time our best answer was that drugs release more dopamine than food does, and that the difference was one of degree. A study published in Nature Neuroscience on September 2, 2026 suggests the difference is also one of kind. Opioids and methamphetamine switch on an emergency power supply inside dopamine nerve endings that a meal never touches.
What the Fudan Team Measured
Xin Pan and colleagues at Fudan University in Shanghai placed a calcium sensor inside the mitochondria of dopamine neurons in mice, specifically at the nerve terminals where those neurons release dopamine into the nucleus accumbens, the hub of the brain's reward circuit. Mitochondria are the structures that produce ATP, the molecule a cell spends as energy. When calcium enters a mitochondrion through a channel called the mitochondrial calcium uniporter, or MCU, it signals the organelle to increase ATP production quickly.
With that sensor in place, the researchers gave the mice heroin, morphine, methamphetamine, cocaine, or a small food pellet and watched the mitochondria respond. Heroin, morphine, and methamphetamine each caused calcium to pour into the mitochondria at the dopamine terminals, and heroin produced the largest response. Under a miniature two-photon microscope, roughly 84 percent of the mitochondria in view lit up after heroin. Food produced no more change than a saline injection. Cocaine did not trigger the response either, and I will come back to that.
The effect was also local. The calcium surge appeared at the terminals in the nucleus accumbens but not in the cell bodies of the same neurons in the ventral tegmental area, and not at their terminals in the prefrontal cortex. Rather than straining the whole neuron, the drugs were straining the exact spot where dopamine is released into the reward circuit.
Why Opioids and Meth Need the Extra Power
The next question was whether this calcium surge mattered for behavior. The team bred mice that lacked MCU only in dopamine neurons and then repeated the drug exposures. In normal mice, heroin and methamphetamine produced the expected burst of activity in an open field and, in a conditioned place preference test, a strong preference for the chamber where the drug had been given. In the mice without MCU in their dopamine neurons, both responses were blunted. Dopamine release in the nucleus accumbens after heroin or methamphetamine was reduced as well, and across individual animals the size of the mitochondrial calcium surge predicted the size of the dopamine surge.
The reason, as far as the authors can tell, is energy. Drug-driven dopamine neurons fire at an intensity that outruns their normal fuel supply. When the team used optogenetics to drive the neurons at controlled rates, the mitochondrial calcium influx appeared only during high-intensity firing, the kind a drug produces and a meal does not. The calcium tells the mitochondria to make ATP fast enough to keep loading and releasing dopamine. Take away that emergency supply and the neuron cannot sustain the flood, though it can still do its ordinary work. The knockout mice ate, moved, and responded to natural rewards normally, and a compound that blocks MCU reduced drug reward behaviors in ordinary mice in much the same way the gene deletion did.
What This Means for the Person in Recovery
The first thing this study does is add to the evidence against the character-flaw explanation of addiction, which I wrote about in The Brain Disorder Most Doctors Still Treat as a Character Flaw. A person with opioid use disorder is living with a reward circuit that has been pushed into a metabolic state natural pleasures do not produce and cannot compete with on equal terms. That is a biological fact about the drug rather than a verdict on the person.
The second thing it does is explain why our current medications are limited in the way they are. Buprenorphine, methadone, and naltrexone all act at the opioid receptor, upstream of the dopamine neuron. They are effective, but they do not touch the machinery this study describes, and some patients relapse despite taking them faithfully. An MCU-targeted medication would work at a different level entirely. Because the switch is thrown only by drugs, blocking it should leave the ability to enjoy a meal, a conversation, or a walk on the beach intact. Earlier attempts to block dopamine signaling directly did reduce drug seeking in animals, but at the cost of depression-like symptoms and motor problems, which is why they never became treatments.
This is a mouse study, and the distance between it and a prescription is real. The MCU blockers that exist today are research tools or older drugs with toxicity that rules them out for this purpose, and no human trial has been run. The cocaine finding marks another limit. Cocaine raises dopamine by blocking its reuptake rather than by driving the neuron to fire harder, and it did not use this pathway, so a future MCU drug may help with opioids and methamphetamine and do nothing for cocaine. For methamphetamine, which still has no approved medication, that would be a meaningful advance, a gap I described in Meth Addiction Has No Medication. Inflammation May Be the Key.
The third thing this study does is give a mechanistic reason to take brain energy metabolism seriously during recovery. Months of pushing dopamine terminals into an emergency fueling state is a metabolic injury, and it fits with what I see clinically: the exhaustion, the flat affect, and the slow return of ordinary pleasure in the first year. That is why brain nutrition, mitochondrial support, and inflammatory markers are part of the workup at Rescue From Rehab, and why we draw on formulations from Action Potential Supplements where the evidence supports them. A mouse study is not a prescription for any supplement, and the value here is in the direction it points.
What to Do With This Now
If you or someone you love is in treatment for opioid or methamphetamine use disorder, stay on the medication that is working. Nothing in this paper argues against buprenorphine or methadone, and the field is years away from an MCU drug. What you can take from this paper today is a better explanation. The craving that makes an ordinary good day feel dim is not weakness of will. It is a reward circuit that was forced to run on emergency power, and that circuit does recover. It recovers on a timeline of many months rather than weeks, as I described in Addiction Recovery Takes 18 Months, Not 28 Days, and it recovers faster when the brain is fed, rested, and protected from inflammation while it rebuilds.
For decades we asked people to fight a metabolic process with willpower and then blamed them when the process won. Studies like this one move the blame where it belongs, onto the biology, and they move the hope where it belongs too, onto treatments that can finally reach it.
Illustration created with AI image tools.
This article was drafted with the assistance of AI writing tools, then reviewed, edited, and approved by Dr. Drew W. Edwards, Ed.D., who holds full editorial responsibility for its content.
References
- Gao, J., Zhao, H., Han, X., Zeng, L., Pan, J., Liu, G., Wei, X., Liu, C., Wu, W., Chen, S., Chen, J., Li, T., Yin, J., Zhou, T., Zhang, X.-M., Li, A.-L., Li, T., & Pan, X. (2026). Mitochondrial calcium influx-driven bioenergetics selectively enable drug addiction. Nature Neuroscience. Published online September 2, 2026. https://doi.org/10.1038/s41593-026-02421-x
- Gao, J., et al. (2025). Mitochondrial calcium influx-driven bioenergetics in the dopaminergic system selectively enable drug reward. bioRxiv preprint (open access full text). https://www.biorxiv.org/content/10.1101/2025.06.10.658191v1.full
- Medical Xpress. (September 2026). Cellular "energetic switch" could help separate drug rewards from natural pleasure. https://medicalxpress.com/news/2026-09-cellular-energetic-drug-rewards-natural.html
- Volkow, N. D., & Boyle, M. (2018). Neuroscience of addiction: relevance to prevention and treatment. American Journal of Psychiatry, 175(8), 729-740. https://doi.org/10.1176/appi.ajp.2018.17101174